{
  "created_at": "Fri Sep 24 8:25:1 +0000 2021",
  "id_str": "1441263744928161793",
  "full_text": "Both DNA and mRNA vaccines have robust safety records and far lower production costs than conventional ones https://t.co/FrJe2PLIR6",
  "display_text_range": [
    0,
    131
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/FrJe2PLIR6",
        "expanded_url": "https://econ.st/3o60ur0",
        "display_url": "econ.st/3o60ur0",
        "indices": [
          108,
          131
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 31,
  "favorite_count": 89,
  "possibly_sensitive": false,
  "original_created_at": "Fri Sep 24 04:50:28 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "DNAワクチンとmRNAワクチンは、いずれも安全性が高く、従来のワクチンに比べて製造コストがはるかに低い。https://t.co/FrJe2PLIR6"
    },
    {
      "locale": "zh",
      "full_text": "DNA和mRNA疫苗都有健全的安全记录，而且生产成本远远低于传统疫苗https://t.co/FrJe2PLIR6。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "DNA和mRNA疫苗都有健全的安全記錄，而且生產成本遠遠低於傳統疫苗https://t.co/FrJe2PLIR6。"
    }
  ]
}